Clinical Trials Browser

Phase 2 × Pathologic Complete Response × Clear all

NCT07586813 2026-05-14

N01-A-PICIT-GI

Phase 2 Recruiting

Classical hematologyGastrointestinal

Pathologic Complete Response, Digestive System Neoplasms, Gastrointestinal Neoplasms, Pancreatic Neoplasms, Thrombocytopenia, Colorectal Neoplasms

NCT07586826 2026-05-14

N01-A-PICIT-GT

Phase 2 Recruiting

BreastClassical hematologyGynecologicThoracic

Pathologic Complete Response, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Thrombocytopenia, Endometrial Neoplasms

NCT01042379 2026-05-06

I-SPY

Phase 2 Recruiting

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT06647680 2026-03-06

Neoadjuvant Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer（CONTROL-01）

Phase 2 Recruiting

Gastrointestinal

Pathologic Complete Response, Rectal Neoplasms

NCT07397442 2026-02-11

Short-Course Radiotherapy Combined With Chemotherapy and Immunotherapy in Mid-Low Locally Advanced Rectal Cancer

Phase 2 Not yet recruiting

Gastrointestinal

Pathologic Complete Response, Rectal Neoplasms

NCT07353723 2026-01-20

Nimotuzumab Combined With Toripalimab and Chemotherapy for Locally Advanced Tonsillar Cancer

Phase 2 Recruiting

Pathologic Complete Response, Head and Neck Neoplasms

NCT07007052 2025-11-26

TAGVEN

Phase 2 Not yet recruiting

Pathologic Complete Response, Blastic Plasmacytoid Dendritic Cell Neoplasm

NCT06811844 2025-07-01

Two-cycle and Three-cycle Induction Therapy With Modified TPF Regimen Combined and Camrelizumab for LANPC

Phase 2 Recruiting

Pathologic Complete Response, Nasopharyngeal Neoplasms

NCT06927180 2025-06-23

SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC

Phase 2 Recruiting

Pathologic Complete Response, Breast Neoplasms

NCT05918328 2025-03-07

Comparing the Efficacy of Nab-PH+Pyrrolitinib and TCbHP in the Neoadjuvant Treatment of HER2 Positive BC

Phase 2 Recruiting

Pathologic Complete Response, Breast Neoplasms

NCT06276868 2024-12-17

Darsilide Combined With AI, Trastuzumab and Patuzumab in the Neoadjuvant Treatment of HR+/HER2+ Breast Cancer

Phase 2 Recruiting

Pathologic Complete Response, Breast Neoplasms

NCT01266083 2024-11-19

WT1 Vaccine Treatment of Patients in Remission From Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL)

Phase 2 Completed

22 enrolled 8 charts

LymphoidOther hematologic neoplasm

Pathologic Complete Response, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04435197 2024-07-03

PALACE-2

Phase 2 Completed

Gastrointestinal

Esophageal Squamous Cell Carcinoma, Pathologic Complete Response

NCT01340430 2024-05-09

Neoadjuvant 5-fluorouracil, Epirubicin and Cyclophosphamide (FEC) Followed by Weekly Paclitaxel and Trastuzumab in Her2 Positive Breast Cancer

Phase 2 Completed

Pathologic Complete Response

NCT05659056 2024-04-16

Neoadjuvant Study With Pyrotinib and Trastuzumab and Abraxane in Patients With HER2-enriched Breast Cancer

Phase 2 Unknown

Pathologic Complete Response, Breast Neoplasms

NCT01686334 2024-03-12

WIDEA

Phase 2 Active not recruiting

Other hematologic neoplasm

Pathologic Complete Response, Leukemia, Myeloid, Acute

NCT05103293 2023-12-27

PTC Guiding Neoadjuvant Treatment in Breast Cancer

Phase 2 Completed

BreastOther neoplasm

Pathologic Complete Response, Breast Neoplasms, Pathological Conditions, Signs and Symptoms

NCT06180863 2023-12-26

Oral Azacitidine (CC-486) Epigenetic Priming and Maintenance for Adult Acute Myeloid Leukemia (AML) Patients

Phase 2 Withdrawn

Other hematologic neoplasm

Pathologic Complete Response, Leukemia, Myeloid, Acute

NCT05371860 2023-09-22

Radiation Omission in Patients With HER2 Overexpressing Tumors With Pathologic Complete Response

Phase 2 Withdrawn

Pathologic Complete Response, Breast Neoplasms

NCT05763992 2023-05-18

BREAKFAST-2

Phase 2 Unknown

Pathologic Complete Response, Breast Neoplasms, Fasting, Triple Negative Breast Neoplasms

NCT04781725 2021-11-17

INVINCIBLE TRIAL: Intratumoral INT230-6 in Breast Cancer

Phase 2 Unknown

Pathologic Complete Response, Breast Neoplasms

NCT01392183 2021-09-20

Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC)

Phase 2 Completed

69 enrolled 15 charts

Pathologic Complete Response, Carcinoma, Renal Cell, Kidney Neoplasms, Neoplasm Metastasis

NCT03417427 2020-04-27

A Clinical Trail of Demethylation Drug Combined With Chemotherapy in Intermediate-risk AML

Phase 2 Unknown

Other hematologic neoplasm

Pathologic Complete Response, Leukemia, Myeloid, Leukemia, Myeloid, Acute

NCT04006041 2019-12-26

Combination of Toripalimab and Neoadjuvant Chemoradiotherapy in Esophageal Cancer

Phase 2 Unknown

Gastrointestinal

Esophageal Squamous Cell Carcinoma, Pathologic Complete Response

NCT02353858 2018-02-13

HT01

Phase 2 Completed

Gastrointestinal

Hyperthermia, Pathologic Complete Response, Rectal Neoplasms

NCT01830244 2017-07-02

Neonab

Phase 2 Unknown

Pathologic Complete Response, Breast Neoplasms

NCT01843179 2017-02-17

Sulindac for Patients With AML

Phase 2 Withdrawn

Other hematologic neoplasm

Pathologic Complete Response, Leukemia, Myeloid, Acute

NCT02511847 2016-04-15

Trial of Afatinib With Paclitaxel for Neoadjuvant Therapy of TNBC and Research of Biomarkers of Afatinib

Phase 2 Unknown

Pathologic Complete Response, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT00636441 2015-12-11

Trial to Evaluate Genomic Expression Profiles to Direct Preoperative Chemotherapy in Early Stage Breast Cancer

Phase 2 Terminated

56 enrolled 16 charts

Pathologic Complete Response, Breast Neoplasms

NCT02059876 2014-02-12

Dose-dense (Biweekly) Carboplatin Plus Paclitaxel With or Without Trastuzumab as Neoadjuvant Treatment for Breast Cancer

Phase 2 Unknown

Pathologic Complete Response, Breast Neoplasms

NCT01566799 2012-03-30

Metformin Plus Neoadjuvant Chemotherapy in Breast Cancer

Phase 2 Unknown

Pathologic Complete Response

NCT01203267 2010-09-16

Weekly Paclitaxel Plus Carboplatin in Preoperative Treatment of Breast Cancer

Phase 2 Completed

Pathologic Complete Response, Breast Neoplasms

NCT00343720 2008-03-13

Study of Alimta® (Pemetrexed) Plus VELCADE® (Bortezomib) or Alimta Alone or VELCADE Alone in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Prior Therapy

Phase 2 Completed

Pathologic Complete Response, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis